Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC	Esophageal Cancer by AJCC V8 Stage	Recruiting	Phase 2	2024-11-21		NCT05738434

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
The First Affiliated Hospital of Zhengzhou University	203

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	China	125

Clinical trials